美通社

2024-10-10 06:16

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest pharmaceutical and biotech exhibition—held in Milan, Italy. In addition, Daewoong will continue to expand the global reach of its innovative new drugs, Fexuprazan and Enavogliflozin.

Daewoong participated in CPHI in 2023, held in Barcelona, where it showcased its success in developing innovative drugs for the second consecutive year. At this year's CPHI in Milan, Daewoong aims to achieve its 'One Product, One Trillion Won' vision by expanding its global footprint and unveiling new drug delivery technologies.

At the forefront of Daewoong's innovations is the microneedle technology, which is poised to revolutionize drug delivery systems.

While traditional injectable drugs reliably deliver medication into the body, they often come with pain and require clinical visits. In contrast, microneedles—composed of tiny needles—eliminate the fear of injections and reduce the need for hospital visits, significantly improving patient-compliance. Though many companies have pursued microneedle-based drugs, none have successfully commercialized them. To date, available microneedle products are limited to cosmetic patches.

Daewoong's subsidiary, Daewoong Therapeutics, has developed an innovative microneedle platform called 'CLOPAM ® ,' which enhances drug uniformity and stability through Aerodynamic crafting and Hermetic packaging. This platform overcomes the issues of contamination and drug inconsistency that have plagued previous microneedle technologies.

The CLOPAM ® microneedle patch, measuring1 cm² and contains approximately 100 microneedles, dissolves upon skin penetration to release the medication. With recognition as a key future technology for Daewoong, CLOPAM ®  has garnered six international patent applications (PCT) and 23 domestic patents (five registered).

Additionally, Daewoong Therapeutics recently received approval from Korea's Ministry of Food and Drug Safety to conduct a Phase 1 clinical trial for a human growth hormone microneedle patch—the first case of a dissolvable microneedle in Korea. The company is also actively developing microneedle-based treatments for diabetes and obesity using Semaglutide, as well as a neurological treatment using its botulinum toxin.

In addition to its microneedle technology, Daewoong will showcase its long-acting Semaglutide injection for obesity treatment. This once-monthly injectable slowly releases Semaglutide, maintaining therapeutic levels for 30 days. This approach addresses a significant gap in the market, where current obesity treatments often necessitate daily or weekly injections. Daewoong's microneedle patch and once-monthly injection, both under development, are poised to outpace competitors, offering patients a less painful and more convenient solution.

Daewoong will also introduce a new patient-friendly colonoscopy bowel preparation (DWRX1010). Traditional preparations for colonoscopy often involve unpleasant tastes, large water intake, or swallowing large pills, causing discomfort for patients and sometimes deterring them from undergoing the procedure. Daewoong's newly developed mini tablet is easy to swallow, offering a more convenient solution for patients preparing for a colonoscopy.

Doyoung Kim, head of Daewoong's global business center, commented, "This marks our 10th year participating in CPHI, and the market now demands not just raw materials and finished products but also technologies that meet consumer needs. With each year, Daewoong's global standing rises, especially with the launch of new drugs and technologies. We are committed to fostering blockbuster products through innovative drug delivery technologies, further solidifying our leadership in the global healthcare market alongside the success of Fexuprazan and Enavogliflozin."

 

source: Daewoong Pharmaceutical Co., Ltd

【你點睇?】澤連斯基與特朗普會面不歡而散,你認為美烏最終能否達成協議?英法或組「意願聯盟」,你認為歐洲有否能力促成俄烏和談?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
9
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
10
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
11
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
12
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
13
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
14
高息定存 | 信銀國際12個月港元定存高達3.5厘
15
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
16
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
17
民營企業座談會 | 習近平在京出席民營企業座談會
18
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
19
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
20
David Webb:因病情惡化,將有序結束個人財經網站
21
2025強積金整合獎賞一覽 轉供應商最多竟然可賺!?
22
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
23
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
24
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
25
港股 | 蕭猷華:恒指升勢可持續?
26
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
27
美股收盤 | 美股三大指數收市報跌,道指跌近750點
28
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
29
港股 | 蕭猷華:恒指上半年目標25000點
30
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老